LitCovid-sentences  

PMC:7200337 / 107331-110767 JSONTXT 9 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T638 0-16 Sentence denotes Vaccine Pipeline
T639 17-290 Sentence denotes For SARS-CoV-1 and MERS-CoV, animal studies and phase I clinical trials of potential vaccines targeting the S protein had encouraging results, with evidence of nAb induction and induction of cellular immunity (Lin et al., 2007, Martin et al., 2008, Modjarrad et al., 2019).
T640 291-407 Sentence denotes These findings are being translated into SARS-CoV-2 vaccine development efforts, hastening the progress drastically.
T641 408-567 Sentence denotes The WHO provided a report in April that reported 63 vaccine candidates in preclinical testing and three in clinical testing (World Health Organization, 2020b).
T642 568-674 Sentence denotes A recent search on May 1, 2020 on ClinicalTrials.gov revealed 10 registered vaccine candidates (Table 5 ).
T643 675-858 Sentence denotes The University of Pittsburgh is also looking to move their microneedle array vaccine candidate containing a codon-optimized S1 subunit protein into clinical trials (Kim et al., 2020).
T644 859-1123 Sentence denotes Sanofi and GlaxoSmithKline (GSK) have recently reported their intent to collaborate and bring together Sanofi’s baculovirus expression system, which is used to produce the influenza virus vaccine, Flublok, to create an S protein vaccine adjuvanted with GSK’s AS03.
T645 1124-1324 Sentence denotes Sinovac Biotech will also enter testing in a clinical trial in China after it was found to protect rhesus macaques from viral challenge without signs of detectable immunopathology (Gao et al., 2020c).
T646 1325-1595 Sentence denotes Although some of these vaccine candidates are based on platforms that have been used or tested for other purposes, there remain questions regarding their safety and immunogenicity, including the longevity of any induced responses, that will require continual evaluation.
T647 1596-1663 Sentence denotes Table 5 Vaccine Candidates Currently Registered for Clinical Trials
T648 1664-1737 Sentence denotes Candidate Design Developer Similar Strategy ClinicalTrials.gov Identifier
T649 1738-1867 Sentence denotes mRNA-1273 LNP-encapsulated mRNA for full-length S protein ModernaTX CMV (John et al., 2018), ZKV (Pardi et al., 2017) NCT04283461
T650 1868-2049 Sentence denotes BNT162a1, b1, b2, c2 LNP-encapsulated mRNA vaccines with different formats of RNA and targets, two for larger S sequence and two for optimized RBD BioNTech SE and Pfizer NCT04368728
T651 2050-2193 Sentence denotes INO-4800 DNA vaccine for full-length S protein Inovio Pharmaceuticals MERS-CoV (Modjarrad et al., 2019), HPV (Trimble et al., 2015) NCT04336410
T652 2194-2354 Sentence denotes Ad5-nCoV adenovirus type 5 encoding full-length S protein CanSino Biologics EBV (Zhu et al., 2015, Zhu et al., 2017) NCT04313127 (phase I)NCT04341389 (phase II)
T653 2355-2506 Sentence denotes ChAdOx1 nCoV-19 adenovirus encoding full-length S protein University of Oxford MERS-CoV (Alharbi et al., 2017), IAV (Antrobus et al., 2014) NCT04324606
T654 2507-2705 Sentence denotes COVID-19 LV-SMENP-DC dendritic cells infected with lentivirus expressing SMENP minigenes to express COVID-19 antigens, together with activated CTLs Shenzhen Geno-Immune Medical Institute NCT04276896
T655 2706-2852 Sentence denotes COVID-19 aAPCs aAPCs infected with lentivirus expressing minigenes to express COVID-19 antigens Shenzhen Geno-Immune Medical Institute NCT04299724
T656 2853-3000 Sentence denotes bacTRL-Spike-1 live bacteria delivering plasmid encoding S protein Symvivo Corporation therapeutics reviewed (Charbonneau et al., 2020) NCT04334980
T657 3001-3108 Sentence denotes PiCoVacc inactivated SARS-CoV-2 vaccine Sinovac Biotech HAV, IAV, IBV, poliovirus, rabies virus NCT04352608
T658 3109-3211 Sentence denotes SARS-CoV-2 rS spike protein nanoparticle vaccine with or without Matrix-M adjuvant Novavax NCT04368988
T659 3212-3436 Sentence denotes aAPCs, artificial antigen-presenting cells; CMV, cytomegalovirus; EBV, Ebola virus; HAV, hepatitis A virus; HPV, human papillomavirus; IAV, influenza A virus; IBV, influenza B virus; LPN, lipid nanoparticle; ZKV, Zika virus.